In Brief: Rhone-Poulenc Rorer's Lovenox
Executive Summary
Rhone-Poulenc Rorer's Lovenox: Approved for additional indication of prevention of deep vein thrombosis, which may lead to pulmonary embolism, following knee replacement surgery, making Lovenox (enoxaparin) the first low molecular weight heparin approved for this indication in the U.S., the company announces March 16. Lovenox was approved for prevention of DVT following hip replacement surgery in 1993...